Pharmaceutical Executive Spotlights Patient Advocacy and the New Faces of Change in Latest Issue
Pharm Exec spoke with leaders in a resurgent patient movement about compassionate use access to new drugs, clinical trial participation policy, and the individual unmet needs of patients suffering from dementia and cancer.
Pleas for compassionate use access are on the increase, and
"We call it wildfire," says Cayo-Cotter. "When one person starts a petition for access to a drug, you'll start to see dozens and dozens of petitions...that ends up creating a space for there to be a real policy change, or an industry shift around an issue."
Like the AIDS activist groups ACT UP and TAG, and their impact on US compassionate use policy in the 1980s, Change.org is in a position to push regulators and the drug industry to rethink issues that separate the medical establishment from its patients.
"Anybody can use Change.org," says Cayo-Cotter. "It can raise a patient's profile in a way that was impossible even three years ago."
"Patient advocacy groups are expanding beyond the traditional boundaries and roles that used to separate individual players in the healthcare system," says PharmExec editor-in-chief William Looney. "There's no commodity more valuable than human health. Expect patient advocacy efforts to continue expanding into areas including R&D, healthcare delivery and global access policy."
Other patient advocates profiled in THE ACTIVE PATIENT: FACES OF CHANGE include Camila Strassle, an advocate working with the Cystic Fibrosis Foundation; Susan Grant, a patient and filmmaker promoting public awareness of frontotemporal dementia; and Sarah Krug, executive director at Cancer101, an organization that provides education to cancer patients based on individual needs.
For more information, contact: Ben Comer (212) 951-6738,
Read more news from Pharmaceutical Executive.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025